Rik Johannes Leonardus van der Lans (Rik J L van der Lans, Rik van der Lans)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Prognostic Factors

Atopic Dermatitis

Cross Sectional

Top Venues

Expert review of clinical immunology

The Laryngoscope

This page only lists publications with an associated author ORCID identifier.

Publications

Rik Johannes Leonardus van der Lans, Josje Janna Otten, Gwijde Flavius Jacobus Petrus Maria Adriaensen, Dinand Rienk Hoven, Linda Berendina Benoist, Wytske Johanna Fokkens, Sietze Reitsma
Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy (2023)
Josje Otten, Rik Johannes Leonardus van der Lans, Eugenio de Corso, Kanstantsin Dziadziulia, Bart Hilvering, Els Weersink, Matteo Bonini, Jan Hagemann, Wanrawee Thaitrakool, Claudio Montuori, Ludger Klimek, Sietze Reitsma, Wytske Fokkens
Evaluation of switching or simultaneous use of biologic treatment in patients with severe chronic rhinosinusitis with nasal polyps and severe asthma. Considerations in clinical decision making. Expert review of clinical immunology (2023)
Korneliusz Golebski, Rik Johannes Leonardus van der Lans, Danielle van Egmond, Esther de Groot, Hergen Spits, Anke H Maitland-van der Zee, Cornelis Maria van Drunen, Wytske Johanna Fokkens, Sietze Reitsma
Inflammatory innate lymphoid cells predict response speed to dupilumab in chronic rhinosinusitis with nasal polyps. Allergy (2023)
Rik Johannes Leonardus van der Lans, Erik van Spronsen, Wytske J Fokkens, Sietze Reitsma
Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report. The Laryngoscope 131 (12) (2021)
Rik Johannes Leonardus van der Lans, Wytske Johanna Fokkens, Gwijde Flavius Jacobus Petrus Maria Adriaensen, Dinand Rienk Hoven, Joekio Jade Drubbel, Sietze Reitsma
Real-life observational cohort verifies high efficacy of dupilumab for Chronic Rhinosinusitis with Nasal Polyps. Allergy (2021)